The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process and this is already happening.

This article highlights the performance last week of the 10 clinical-stage AI-powered and psychedelic compound-based drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio,

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and MTD, and their areas of focus.

The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.

9 micro/small cap AI stocks are still in bubble mode advancing 14.8%, on average, last week. In comparison, the Global X Artificial Intelligence & Technology ETF was only up 0.5% and the iShares Semiconductor ETF was only up 1.6%.